Why Advanced HS Is Not Simply More of Early HS
A common way to think about HS progression is quantitative: more episodes, more locations, more severe. This framing implies that Stage III HS is essentially Stage I HS turned up in intensity — that the underlying process is the same, just more active. It implies, in turn, that what works at Stage I should work at Stage III if applied with sufficient force.
This is incorrect. Advanced HS is not simply intensified early HS. It is qualitatively different — not just in its clinical expression but in the tissue environment in which it is operating. The local architecture of the skin in repeatedly affected areas has been progressively altered by cumulative inflammatory damage. The vasculature, the connective tissue, the follicular structure, and the local immune environment have all changed in ways that make both the disease process and the healing response operate differently than they did in early-stage tissue.
Understanding the mechanism of this cumulative tissue alteration — and particularly the role of microvascular damage — helps explain several clinical observations that otherwise appear puzzling: why advanced HS heals more slowly and incompletely, why it is more painful, why it responds more poorly to treatments that work at earlier stages, and why tissue restoration must be an explicit component of treatment at later stages rather than an expected by-product of inflammation reduction.
"To understand why this condition keeps recurring, it's important to look beyond the surface and examine the internal processes involved."
The Local Vascular Response to Inflammation
When inflammation occurs in any tissue, the local vasculature responds immediately: small blood vessels dilate, vascular permeability increases to allow immune cells and inflammatory mediators to reach the site, and the local blood flow pattern changes to support the inflammatory response. In a single, acute episode, this vascular response is both necessary and appropriate — it delivers the immune resources needed to manage the inflammatory event, and when the episode resolves, the vasculature largely returns to its baseline state.
In HS, this vascular response occurs repeatedly in the same tissue locations. Each episode brings the same cascade of vascular activation. And each resolution is incomplete — not in a clinically obvious way, but in a cumulative way. The small blood vessels and capillaries in repeatedly inflamed areas undergo progressive structural change with each cycle. Vascular walls thicken. Permeability changes become partially permanent rather than fully reversing between episodes. The local pattern of blood flow shifts in ways that favour a persistently inflammatory local environment even between active episodes.
Over time, this cumulative vascular change alters the baseline state of the affected tissue. An area that has experienced twenty or thirty inflammatory cycles over several years has a fundamentally different local vascular environment than tissue experiencing its first or second episode. It is more readily recruited into new inflammatory episodes. It provides poorer perfusion for healing. It is less responsive to interventions that depend on normal vascular delivery mechanisms to reach the target tissue.
Lymphatic Involvement
Alongside arterial and venous microvascular damage, HS progressively impairs local lymphatic function. The lymphatic system is responsible for clearing inflammatory debris, excess fluid, and immune cells from inflamed tissue. When lymphatic vessels in repeatedly affected areas are structurally damaged — which occurs progressively through repeated cycles of inflammation and partial healing — their drainage capacity is reduced. This means that the inflammatory material generated by each episode is cleared more slowly and less completely, leaving a higher residual inflammatory burden between episodes.
This lymphatic impairment creates a self-reinforcing cycle: each episode generates inflammatory material that is inadequately cleared, contributing to a persistently inflamed local environment that lowers the threshold for the next episode. The lymphatic damage that produces this impairment accumulates with each cycle and does not reverse spontaneously — it requires active tissue restoration as part of treatment.
In Ayurvedic understanding, microvascular and lymphatic damage in HS corresponds to the progressive impairment of the body's channel system (Srotas) — the pathways through which nutrients reach tissues and waste is removed. When these channels become damaged and obstructed through repeated inflammation (Srotorodha), both nourishment and clearance are compromised simultaneously. This is why Ayurvedic treatment in advanced HS includes specific interventions directed at channel restoration and lymphatic support — not as supplementary measures, but as primary therapeutic targets without which tissue correction remains incomplete.
The Consequence for Healing
Normal wound and tissue healing depends critically on adequate vascular delivery — of oxygen, of growth factors, of the cellular components that build new connective tissue and restore tissue architecture. When the local vasculature is progressively damaged by repeated inflammation, this delivery is compromised. Healing becomes slower, less complete, and less structurally accurate.
This is why the skin over repeatedly affected HS areas heals differently from normal skin. It heals with more fibrosis — the body's compensatory response to impaired regenerative healing is to lay down collagen-rich scar tissue, which provides structural closure but not functional restoration. The result is the progressive induration and scarring characteristic of long-standing HS — not primarily as a direct consequence of inflammation, but as a consequence of impaired healing in a compromised vascular environment.
The clinical implication is significant: reducing inflammation in advanced HS is necessary but not sufficient to produce tissue recovery. The tissue also needs active support for vascular restoration and regenerative healing. Without this, inflammation reduction produces better-controlled disease in tissue that continues to heal poorly — which is an improvement in one dimension, but not the comprehensive recovery that most patients are seeking.
Pain Amplification Through Vascular Change
The progressive vascular changes in HS-affected tissue also contribute to the amplification of pain that characterises advanced disease. Damaged and remodelled small blood vessels alter the local neural environment — the network of fine nerve endings that accompany the vasculature is affected by the same structural changes. Over time, affected areas develop a degree of peripheral sensitisation: pain responses are triggered at lower thresholds, and the subjective intensity of pain increases even when the objective inflammatory activity may not have worsened.
This is why patients with long-standing HS often describe pain that seems disproportionate to the visible activity of the disease. It is not disproportionate — it is a consequence of cumulative vascular and neural changes that have altered the pain-signalling environment in affected tissue. It also means that pain reduction in advanced HS requires not just inflammation control but tissue-level restoration that addresses the structural changes underlying sensitisation.
The Fibrotic Transition
Stage III As microvascular damage accumulates and healing progressively shifts toward fibrotic rather than regenerative repair, the affected tissue undergoes a qualitative change. Areas of dense fibrosis form — not as isolated scars, but as regions of altered tissue architecture that involve multiple follicular structures, the surrounding dermis, and the subcutaneous layer. Within these fibrotic regions, normal follicular function is permanently disrupted. The remaining follicles in the area are structurally abnormal, embedded in a poorly vascularised collagen matrix, and surrounded by a chronically altered immune environment.
These fibrotic regions behave differently from normal or even inflamed HS tissue. They are less responsive to systemic treatment because the vascular delivery required to get therapeutic agents to the target tissue is impaired. They may generate chronic low-grade discharge even in the absence of acute inflammatory episodes, because the structural environment is irreversibly altered. And they create a reservoir of chronically activated immune cells and inflammatory signals that maintain a persistently elevated local inflammatory baseline.
Why This Matters for Treatment Sequencing
The progressive nature of microvascular damage in HS has direct implications for how treatment should be structured, particularly in patients with longer-standing disease.
In early-stage HS, the tissue environment is structurally intact. Correcting the internal drivers — gut, hormonal, immune — allows the tissue to recover through its own regenerative capacity. The vascular environment is not significantly compromised, delivery of therapeutic benefit is efficient, and healing is structurally adequate.
In established HS with significant microvascular involvement, systemic correction alone is insufficient. The local tissue environment has been altered in ways that impair healing and reduce therapeutic responsiveness. Treatment must include components that specifically address tissue restoration: improving local circulation and lymphatic drainage, supporting regenerative rather than fibrotic healing, and restoring the vascular delivery capacity that allows therapeutic agents to reach their target.
This is why treatment at later stages takes longer, requires more comprehensive engagement, and must be evaluated against different short-term expectations. The system being corrected is more complex — it includes not just the systemic drivers that generated the disease but the structural consequences that those drivers have produced in the local tissue environment over years of activity.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
The Argument for Earlier Intervention
The cumulative nature of microvascular damage in HS provides perhaps the clearest argument for earlier intervention. Each inflammatory cycle deposits damage that does not fully reverse. Each year of uncorrected internal disease is not simply another year at the same level of tissue involvement — it is a year in which the local structural environment progressively moves away from the state in which comprehensive recovery is achievable.
This does not mean that later-stage correction is impossible or without value — it is both possible and necessary, and the structural changes of advanced HS are substantially reversible with appropriate treatment over adequate time. But the degree of reversibility and the time required for recovery both increase as microvascular damage accumulates. Earlier correction is categorically easier — and more complete in its outcomes — than later correction, for reasons that are structural rather than simply conceptual.
For patients currently at an early or moderate stage of disease, this is the most practically significant information: the tissue environment in which you are currently managing HS is more responsive than the one that will exist if the progression continues uncorrected. The window for comprehensive recovery is open — and the question is whether intervention is directed at the internal drivers now, or whether it continues to manage episodes while the structural environment progressively changes beneath the surface.